TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02646631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants assigned to this treatment will receive the usual care as determined by their physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to this treatment will receive the usual care as determined by their physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants assigned to this treatment will receive the usual care as determined by their physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Management of Risks in Epilepsy (MORE)
Description: MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Management of Risks in Epilepsy (MORE)
Description: MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based motivational interviewing (MORE+MI)
Description: Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Printed educational materials on the management of epilepsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Printed educational materials on the management of epilepsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Printed educational materials on the management of epilepsy
Study: NCT02961959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Arthrodesis of SI-joints, Physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgery
Description: Physiotherapy
Study: NCT02151552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F](+/-)NOS
Description: 7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study: NCT04279873

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological diagnostics on pulmonary secretion
Description: Culture, 16s, 18s, next generation sequencing
Study: NCT02218645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE 941 OD tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brotizolam
Study: NCT00746278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy using bipolar
Description: Laparoscopic ovarian cystectomy using bipolar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy using ultrasonic scalpel
Description: Laparoscopic ovarian cystectomy using ultrasonic scalpel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cystectomy using suture
Description: Laparoscopic ovarian cystectomy using suture
Study: NCT00130169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7974
Description: Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
Study: NCT01367834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatotropin
Description: Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
Study: NCT00240461

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: COLD-fX natural health product
Description: 200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: COLD-fX
Description: 400 mg COLD-fX natural health product 2 times daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: crystalline substance 200 mg twice daily for 6 months
Study: NCT05114408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 week trimodal prehabilitation course
Description: trimodal prehabilitation in mixed: stationary and at-home structure
Study: NCT03686904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzalkonium Gel
Description: antibiofilm solution (BlastX) topical wound gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzalkonium Gel
Description: antibiofilm solution (BlastX) topical wound gel
Study: NCT02190162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tantum Verde® mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Mouthwash with placebo solution
Study: NCT03712462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Weight Loss Therapy for BED
Description: ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavior Therapy
Description: SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
Study: NCT02594566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyMVectin
Description: CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
Study: NCT01307189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium diskus inhalation powder, 18ug, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo diskus inhalation powder, once daily
Study: NCT02001662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group, block no. 1 - Ropivacain
Description: Intervention group: 1. block ropivacaine - 2. block saline

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group: 1. block - saline
Description: Control group: 1. block saline - 2. block ropivacaine
Study: NCT03148912

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm
Description: The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
Study: NCT00379821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Description: Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
Study: NCT03686904

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care topical gel
Description: standard of care topical gel (hydrocolloid topical gel)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care topical gel
Description: standard of care topical gel (hydrocolloid topical gel)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wound (in clinic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wound (in clinic)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wound (in clinic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wound (in clinic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzalkonium irrigation
Description: washing and lavaging in clinic with benzalkonium irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzalkonium irrigation
Description: washing and lavaging in clinic with benzalkonium irrigation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Irrigation (SOC Irrigation)
Description: Normal Saline Irrigation (SOC Irrigation)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Irrigation (SOC Irrigation)
Description: Normal Saline Irrigation (SOC Irrigation)
Study: NCT00870181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADV-TK/GCV
Description: gene therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study: NCT00379821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
Study: NCT00870181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy
Study: NCT03355846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella
Description: after meals twice a day for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proctocella
Description: after hygiene treatment for 4 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonil® cps
Description: after meals twice a day for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonil® Cream
Description: treatment for 4 weeks;~.
Study: NCT01762800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
Description: Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
Study: NCT03855774

Intervention type: GENETIC
Group type: OTHER
Intervention: Polymorphisms
Description: Classification of sleep disorders using 22 genetic polymorphisms
Study: NCT03355846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectalgan Mousse
Description: for 4 weeks
Study: NCT04212598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
Study: NCT04917484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTA-Octreotide
Description: Lu-177-DOTATOC in standard doses or individualized doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lu-177-DOTA-Octreotide
Description: Lu-177-DOTATOC in standard doses or individualized doses.
Study: NCT00724672

Intervention type: DRUG
Intervention: etanercept
Description: etanercept 50 mg subcutaneously once weekly

Intervention type: DRUG
Intervention: infliximab
Description: infliximab 3 mg/kg IV at Weeks 0, 2, and 6

Intervention type: DRUG
Intervention: adalimumab
Description: adalimumab 40 mg subcutaneously biweekly
Study: NCT00672919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
Study: NCT00970112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement
Description: Open flap debridement - access flap + scaling and root planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement
Description: Open flap debridement - access flap + scaling and root planning

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open Flap Debridement
Description: Open flap debridement - access flap + scaling and root planning
Study: NCT03257124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 160mg per oral daily (1 cycle of 28 days)
Study: NCT01176058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anidulafungin/Fluconazole
Description: Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
Study: NCT04203836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 Tablet
Description: film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 Tablet
Description: film-coated tablet
Study: NCT01217463

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study: NCT03337334

Intervention type: DEVICE
Group type: OTHER
Intervention: tACS at tremor frequency
Description: tACS applied between the stimulation electrodes at tremor frequency

Intervention type: DEVICE
Group type: OTHER
Intervention: tACS at tremor frequency
Description: tACS applied between the stimulation electrodes at tremor frequency
Study: NCT03817619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier crushed tablet
Description: Single-dose crushed ELB/GZR in a fasted state.
Study: NCT03125512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night Shift positional device
Description: Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: Automated adjusting continuous positive airway pressure
Study: NCT02327676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients for 48 weeks
Study: NCT02713724

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: limited physical exercise
Description: The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
Study: NCT02686918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Practice Nurse consultation
Study: NCT02041481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor MEK162
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor MEK162
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT03904602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edema Wear fuzzy wale compression garment
Description: net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
Study: NCT02853825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Skill Enhancement
Description: Receive relationship classes with access to parenting, employment services, and financial services.
Study: NCT02041481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT05170217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Inhaled cannabis containing 10mg THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Inhaled cannabis containing 10mg THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Inhaled cannabis containing 10mg THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Inhaled cannabis containing 10mg THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Inhaled cannabis containing 10mg CBD
Study: NCT02041481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study: NCT03641378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention
Description: team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
Study: NCT02882594

Intervention type: BEHAVIORAL
Intervention: Observing patient behaviors for anesthesia induction compliance
Description: Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
Study: NCT01314001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch
Study: NCT05170217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Inhaled cannabis containing 20mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Inhaled cannabis containing 30mg CBD
Study: NCT01314001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine
Description: Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine
Description: Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
Study: NCT03544021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
Study: NCT00182039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release (CR)
Description: Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
Study: NCT03573323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study: NCT03641378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Transplant Care
Description: Standard care per hospital guidelines